DTP3

Research use only, not for human use.

DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.

DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.

——

Animal Model:6 to 8-week old male NOD/SCID mice (NOD.CB17-Prkdcscid/IcrCrl; Charles River) Dosage:14.5 mg/kg Administration:S.c.; daily; 28 days Result:Had shown a dramatic shrinkage of the tumors.Animal Model:CD1 male mice of 25-30 g Dosage:10 mg/kg (Pharmacokinetic Study) Administration:Intravenous injection Result:Had t1/2 of 1.26 hours, CL of 27.13 ML/min/kg, and Vd of 2.80 L/kg.

——

Others

Other Targets

GADD45β/MKK7

——

——

1809784-29-9

525.6

C26H35N7O5

>98% (HPLC)

DMSO:100 mg/ml (190.26 mM); Ethanol:100 mg/ml (190.26 mM); Water:100 mg/ml (190.26 mM)

CC(=O)N[C@H](CC1=CC=C(C=C1)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N

——

(-20℃)

With Ice Pack

≥ 2 years